Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

New Technique Evaluates Reliability of AI-Enabled Medical Imaging

26 August 2026 · By · Wire by Fusion42

Published

26 August 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at technologynetworks.com →

◆ Verified

Fusion42 · 26 August 2026 · Fusion42 review

Wave Neuroscience and Texas A&M Health developed and received FDA clearance for Magnetic e-Resonance Therapy (MeRT), an AI-personalised treatment that significantly reduces PTSD symptoms by targeting brain activity uniquely in each patient, showing a 52% symptom reduction and 68% remission in trials.

This Wire brief sits within Fusion42's coverage of Medtech.

◆ ◆ The Wire takeaway

You must update your mental health AI solutions to match growing regulatory acceptance of personalised brain therapies. This clearance resets expectations for AI’s role in precise diagnostics and tailored treatments.

◆ Coverage

1 source · 26 Aug 2026

◆ Related on Wire

◆ Topics

Medtechptsdai-medicinefda-clearedpersonalised-therapymental-health